POSTER: IBCL-625 Quality of Life (QoL) Outcomes With Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma (R/R FL): Results From a Phase 3, Double-Blind, Randomized, Placebo-Controlled, International, Multicenter Study (inMIND) | Publicación